"World in motion" - emulsion adjuvants rising to meet the pandemic challenges.

ABSTRACT: Emulsion adjuvants such as MF59 and AS03 have been used for more than two decades as key components of licensed vaccines, with over 100 million doses administered to diverse populations in more than 30 countries. Substantial clinical experience of effectiveness and a well-established safety profile, along with the ease of manufacturing have established emulsion adjuvants as one of the leading platforms for the development of pandemic vaccines. Emulsion adjuvants allow for antigen dose sparing, more rapid immune responses, and enhanced quality and quantity of adaptive immune responses. The mechanisms of enhancement of immune responses are well defined and typically characterized by the creation of an "immunocompetent environment" at the site of injection, followed by the induction of strong

SUBMITTER: O'Hagan DT 

PROVIDER: S-EPMC8692316 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature